Long-Acting Injectable Statins-Is It Time for a Paradigm Shift?

Tatham, Lee M ORCID: 0000-0001-9448-8876, Liptrott, Neill J ORCID: 0000-0002-5980-8966, Rannard, Steve P ORCID: 0000-0002-6946-1097 and Owen, Andrew ORCID: 0000-0002-9819-7651
(2019) Long-Acting Injectable Statins-Is It Time for a Paradigm Shift? MOLECULES, 24 (15). E2685-.

[img] Text
Long-Acting Injectable Statins-Is It Time for a Paradigm shift.pdf - Author Accepted Manuscript

Download (231kB) | Preview


In recent years, advances in pharmaceutical processing technologies have resulted in development of medicines that provide therapeutic pharmacokinetic exposure for a period ranging from weeks to months following a single parenteral administration. Benefits for adherence, dose and patient satisfaction have been witnessed across a range of indications from contraception to schizophrenia, with a range of long-acting medicines also in development for infectious diseases such as HIV. Existing drugs that have successfully been formulated as long-acting injectable formulations have long pharmacokinetic half-lives, low target plasma exposures, and low aqueous solubility. Of the statins that are clinically used currently, atorvastatin, rosuvastatin, and pitavastatin may have compatibility with this approach. The case for development of long-acting injectable statins is set out within this manuscript for this important class of life-saving drugs. An overview of some of the potential development and implementation challenges is also presented.

Item Type: Article
Uncontrolled Keywords: nanoparticles, depot, sustained release, adherence
Depositing User: Symplectic Admin
Date Deposited: 01 Aug 2019 09:08
Last Modified: 24 Jan 2024 14:54
DOI: 10.3390/molecules24152685
Related URLs:
URI: https://livrepository.liverpool.ac.uk/id/eprint/3050746